Moreno 2013 Biomed Chromatogr: Difference between revisions
(Created page with "{{Publication |title=Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF, Ruiz-NuΓ±o A (2013) Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry wit...") Β |
No edit summary Β |
||
Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF, Ruiz-NuΓ±o A (2013) Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma. Biomed Chromatogr 27:502-8. Β | |title=Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF, Ruiz-NuΓ±o A (2013) Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma. Biomed Chromatogr 27:502-8. | ||
|info=[ | |info=[http://www.ncbi.nlm.nih.gov/pubmed/23034891 PMID: 23034891] | ||
|authors=Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF, Ruiz-Nuno A | |authors=Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF, Ruiz-Nuno A | ||
|year=2013 | |year=2013 |
Latest revision as of 16:15, 10 October 2016
Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF, Ruiz-NuΓ±o A (2013) Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma. Biomed Chromatogr 27:502-8. |
Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF, Ruiz-Nuno A (2013) Biomed Chromatogr
Abstract: We have developed a method of liquid chromatography in tandem with mass spectrometry to monitor therapeutic levels of imatinib in plasma, a selective inhibitor of protein tyrosine kinase. After solid-phase extraction of plasma samples, imatinib and its internal standard, imatinib-D8, were eluted with Zorbax SB-C18 at 60βΒ°C, under isocratic conditions through a mobile phase consisting of 4βmm ammonium formate, pH: 3.2 (solution A) and acetonitrile solution B. The flow rate was 0.8βmL/min with 55% solution Aβ+β45% solution B. Imatinib was detected and quantified by mass spectrometry with electrospray ionization operating in selected-reaction monitoring mode. The calibration curve was linear in the range 10-5000βng/mL, the lower limit of quantitation being 10βng/mL. The method was validated according to the recommendations of the Food and Drug Administration, including tests of matrix effect (biasβ<β10%) and recovery efficiency (>80 and <120%). The method is precise (coefficient of variance intra-day <2% and inter-day <7%), accurate (95-108%), sensitive and specific. It is a simple method with very fast recording time (1.2βmin) that is applicable to clinical practice. This will permit improvement of the pharmacological treatment of patients.
Copyright Β© 2012 John Wiley & Sons, Ltd.
Labels: